HRTX - Heron Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
HRTX price evolution
HRTX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $18.39 | $20.45 | $28.68 | |
| Short term investments | $48.96 | $51.07 | $51.73 | |
| Net receivables | $67.04 | $73.71 | $65.32 | $60.14 |
| Inventory | $45.95 | $42.86 | $42.47 | $42.11 |
| Total current assets | $195.19 | $191.17 | $185.9 | $188.77 |
| Long term investments | ||||
| Property, plant & equipment | $18.88 | $20.04 | $24.1 | $25.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $26.97 | $31.98 | $33.73 | |
| Total investments | $48.96 | $51.07 | $51.73 | |
| Total assets | $220.78 | $218.14 | $217.89 | $222.51 |
| Current liabilities | ||||
| Accounts payable | $10.19 | $10.23 | $0.84 | $3.24 |
| Deferred revenue | ||||
| Short long term debt | $3.19 | $3.14 | $3.08 | |
| Total current liabilities | $85.54 | $80.32 | $75.38 | $79.69 |
| Long term debt | $149.65 | $175.52 | $176.03 | $176.55 |
| Total noncurrent liabilities | $175.76 | $176.28 | $176.79 | |
| Total debt | $178.71 | $179.17 | $179.63 | |
| Total liabilities | $260.78 | $256.08 | $251.65 | $256.48 |
| Shareholders' equity | ||||
| Retained earnings | -$1923.26 | -$1918.41 | -$1909.17 | -$1906.01 |
| Other shareholder equity | $0.04 | -$0.01 | -$0.01 | $0.01 |
| Total shareholder equity | -$37.94 | -$33.77 | -$33.97 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $28.68 | $15.36 | $90.54 | $105.14 |
| Short term investments | $51.73 | $69.49 | $67.04 | $103.35 |
| Net receivables | $60.14 | $52.05 | $35.5 | $41.85 |
| Inventory | $42.11 | $54.57 | $48.38 | $41.91 |
| Total current assets | $188.77 | $205.44 | $254.42 | $314.2 |
| Long term investments | ||||
| Property, plant & equipment | $25.6 | $29.8 | $33.56 | $39.01 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $33.73 | $45.52 | $51.28 | $39.36 |
| Total investments | $51.73 | $69.49 | $67.04 | $103.35 |
| Total assets | $222.51 | $250.95 | $305.71 | $353.56 |
| Current liabilities | ||||
| Accounts payable | $3.24 | $3.23 | $3.8 | $0.53 |
| Deferred revenue | ||||
| Short long term debt | $3.08 | $2.69 | $2.42 | $10.05 |
| Total current liabilities | $79.69 | $82.36 | $71.06 | $102.5 |
| Long term debt | $176.55 | $149.28 | $157.08 | $14.56 |
| Total noncurrent liabilities | $176.79 | $155.02 | $157.08 | $14.56 |
| Total debt | $179.63 | $157.48 | $159.5 | $24.61 |
| Total liabilities | $256.48 | $237.38 | $228.14 | $117.06 |
| Shareholders' equity | ||||
| Retained earnings | -$1906.01 | -$1795.45 | -$1613.43 | -$1392.75 |
| Other shareholder equity | $0.01 | -$0.02 | -$0.01 | $0.26 |
| Total shareholder equity | -$33.97 | $13.57 | $77.57 | $236.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.02 | $34.67 | $34.23 | |
| Cost of revenue | $10.52 | $8.44 | $9.88 | |
| Gross Profit | $25.51 | $26.23 | $24.35 | |
| Operating activities | ||||
| Research & development | $4.43 | $4.61 | $10.95 | |
| Selling, general & administrative | $27.52 | $26.42 | $23.62 | |
| Total operating expenses | $31.95 | $31.02 | $34.57 | |
| Operating income | -$6.45 | -$4.8 | -$10.22 | |
| Income from continuing operations | ||||
| EBIT | -$9.23 | -$3.16 | -$10.22 | |
| Income tax expense | ||||
| Interest expense | $0.5 | |||
| Net income | ||||
| Net income | -$9.23 | -$3.16 | -$10.72 | |
| Income (for common shares) | -$9.23 | -$3.16 | -$10.72 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $127.04 | $107.67 | $86.35 | $88.64 |
| Cost of revenue | $65.11 | $54.87 | $46.02 | $36.19 |
| Gross Profit | $61.94 | $52.8 | $40.33 | $52.45 |
| Operating activities | ||||
| Research & development | $55.9 | $107.51 | $130.82 | $174.53 |
| Selling, general & administrative | $116.66 | $119.95 | $127.33 | $106.08 |
| Total operating expenses | $172.55 | $233.99 | $258.15 | $280.61 |
| Operating income | -$110.61 | -$181.19 | -$217.83 | -$228.16 |
| Income from continuing operations | ||||
| EBIT | -$110.06 | -$181.19 | -$218.71 | -$229.01 |
| Income tax expense | ||||
| Interest expense | $0.5 | $0.84 | $1.98 | -$1.73 |
| Net income | ||||
| Net income | -$110.56 | -$182.02 | -$220.68 | -$227.28 |
| Income (for common shares) | -$110.56 | -$182.02 | -$220.68 | -$227.28 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$9.23 | -$3.16 | -$10.72 | |
| Operating activities | ||||
| Depreciation | $0.64 | $0.69 | $0.71 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.57 | $3.38 | $4.32 | |
| Total cash flows from operations | -$4.6 | -$9.52 | $2.46 | |
| Investing activities | ||||
| Capital expenditures | -$0.64 | -$0.24 | ||
| Investments | $2.69 | $1.28 | -$8.6 | |
| Total cash flows from investing | $7.3 | $2.05 | $1.28 | -$8.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.49 | $0.01 | $0.2 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.52 | $0.49 | $0.01 | $0.2 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.94 | -$2.06 | -$8.23 | -$6.18 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$110.56 | -$182.02 | -$220.68 | -$227.28 |
| Operating activities | ||||
| Depreciation | $2.9 | $2.89 | $3.02 | $2.85 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $32.85 | $42.98 | $46.85 | $50.22 |
| Total cash flows from operations | -$58.79 | -$146.91 | -$203.35 | -$184.82 |
| Investing activities | ||||
| Capital expenditures | -$1.53 | -$1.6 | -$2.99 | -$6.81 |
| Investments | $19.53 | -$1.73 | $35.72 | $215.77 |
| Total cash flows from investing | $18 | -$3.32 | $32.73 | $208.96 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $29.76 | $75.06 | $7.07 | $9.08 |
| Net borrowings | $24.35 | $148.96 | $0.03 | |
| Total cash flows from financing | $54.11 | $75.06 | $156.03 | $9.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $13.31 | -$75.18 | -$14.6 | $33.24 |
News
Fundamentals
| Market cap | $324.64M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 151.70M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -7.55 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.28 |
| Quick ratio | 1.74 |